An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy

An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy - An open label, randomized study for the comparison of effectiveness between glucagon-like peptide-1 (GLP-1) analogue in people with type 2 diabetes treated bolus first or basal first insulin therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010354

Enrollment

Registered

2013-03-29

Start date

2011-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Liraglutide 0.9mg once a day for 6 months after treating fasting blood glucose with Bolus First(insulin glulisine)insulin therapy Exenatide 10ug twice a day for 6 months after treating fasting blood g

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The subjects must satisfy the following conditions: 1)Age at the time of obtaining informed consentis more than 20 years old 2) Patients with type 2 diabetes, whose HbA1c is more than 7.4% 3) Gender is unquestioned 4) Patients treated with Bolus First or Basal First insulin therapy

Exclusion criteria

Exclusion criteria: 1.Hypersensitivity to components of liraglutide and exenatide 2.None Type 2 diabetes 3.Medical history and/or complication of diabetic ketoacidosis 4.Medical history and/or complication of severe hypoglycemia 5.Severe infection, around surgery or severe trauma 6.Patients who received the administration of DPP-4 inhibitors or GLP-1 analogue within 4 weeks 7.Treatment with glucocorticoid 8.Uncontrolled Hypertension(systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) 9.Proliferative retinopathy or maculopathy 10.History of malignancy 11.Severe health problems not suitable for the study 12.Pregnant or lactating woman 13.Cases that Physicians deem inappropriate as the target of the test

Design outcomes

Primary

Measure	Time frame
insulin dose to safely switch to GLP-1 analogue	—

Countries

Japan

Contacts

Public ContactTAKAMURA Toshinari

kanazawa University Graduate School of Medical Science. kanazawa University Graduate School of Medical Science.

ttakamura@m-kanazawa.jp076-265-2710

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026